Biotech Values

[Cactus Quave]

they (TEVA)are super smart in their PRs.

They are masters of implication (e.g. "Prior to potential final product approval") and cleverly disguised ambiguity (e.g. "Office of Generic Drugs requires responses to a short list of questions, which Teva intends to respond to in the near future.") The implication here is that final product approval simply hinges on TEVA responding in the near future to the FDA's short list of questions. Gee, I wonder what's on the short list if the FDA needs to approve of TEVA's responses?